PT-141 (Bremelanotide)

A melanocortin agonist that increases sexual desire by acting on the central nervous system rather than on blood flow.

FDA-approved·Regulatory status as of May 2026

Relevance for women

FDA-approved (as Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women — the strongest evidence-based peptide option in this category.

Articles on PT-141 (Bremelanotide)

Providers that offer PT-141 (Bremelanotide)

See the full provider comparison for all peptides side by side.